2023
Dermatologic toxicities of chemotherapy: an educational intervention for skin of color women with breast cancer
Ahmad M, Saeed S, Olamiju B, Silber A, Leventhal J. Dermatologic toxicities of chemotherapy: an educational intervention for skin of color women with breast cancer. International Journal Of Women's Dermatology 2023, 9: e073. PMID: 36733315, PMCID: PMC9886509, DOI: 10.1097/jw9.0000000000000073.Peer-Reviewed Original ResearchDermatologic toxicitiesSOC patientsBreast cancerEducational interventionFurther multi-institutional studiesCancer treatmentMulti-institutional studyAfrican American/BlackDermatologic effectsInfusion centerAmerican/BlackPatient educationMinority patientsColor patientsEducational pamphletChemotherapyPatientsLarger sample sizeMedical careSkin typePilot studyHigh school degreeSmall sample sizeSample sizeMost participants
2020
Dermatologic toxicities associated with radiation therapy in women with breast cancer
Ramseier JY, Ferreira MN, Leventhal JS. Dermatologic toxicities associated with radiation therapy in women with breast cancer. International Journal Of Women's Dermatology 2020, 6: 349-356. PMID: 33898697, PMCID: PMC8060663, DOI: 10.1016/j.ijwd.2020.07.015.Peer-Reviewed Original ResearchBreast cancerRadiation therapyDermatologic toxicitiesEarly-stage breast cancerRadiation-induced morpheaAdjuvant radiation therapyBreast-conserving surgeryStage breast cancerStandard of careRadiation-induced fibrosisRadiation recallCutaneous toxicityRadiation dermatitisCutaneous sequelaeClinical presentationCutaneous malignanciesPatients' qualityTherapyCancerWomenToxicityMorpheaSequelaePatientsSurgery
2019
Dermatologic conditions in women receiving systemic cancer therapy
Ferreira MN, Ramseier JY, Leventhal JS. Dermatologic conditions in women receiving systemic cancer therapy. International Journal Of Women's Dermatology 2019, 5: 285-307. PMID: 31909148, PMCID: PMC6938835, DOI: 10.1016/j.ijwd.2019.10.003.Peer-Reviewed Original ResearchDermatologic conditionsDermatologic toxicitiesCancer therapyDermatologic adverse effectsCancer-related survivalImmune checkpoint inhibitorsNumber of patientsSystemic cancer therapyQuality of lifeCheckpoint inhibitorsEndocrine therapyOverall survivalMultidisciplinary careTimely diagnosisTreatment responseTraditional chemotherapyMucosal surfacesTherapyNovel therapeuticsMental healthAdverse effectsWomenToxic effectsCancerSevere instancesThe life-threatening eruptions of immune checkpoint inhibitor therapy
Coleman EL, Olamiju B, Leventhal JS. The life-threatening eruptions of immune checkpoint inhibitor therapy. Clinics In Dermatology 2019, 38: 94-104. PMID: 32197753, DOI: 10.1016/j.clindermatol.2019.10.015.Peer-Reviewed Original ResearchConceptsImmune-related adverse eventsAcute generalized exanthematous pustulosisSevere cutaneous adverse reactionsImmune checkpoint inhibitorsStevens-Johnson syndromeToxic epidermal necrolysisManagement of irAEsImmune checkpoint inhibitor therapyCell death ligand 1Generalized exanthematous pustulosisCheckpoint inhibitor therapyCutaneous adverse reactionsDeath ligand 1Life-threatening presentationCell death 1Cytotoxic T lymphocytesLife-threatening eruptionsDermatologic toxicitiesExanthematous pustulosisICPI therapyNeutrophilic dermatosisCheckpoint inhibitorsEpidermal necrolysisAdverse eventsCutaneous eruption